CT-based Assessment at 6-Month Follow-up of COVID-19 Pneumonia patients in China.

Publication date: Feb 29, 2024

This study aimed to assess pulmonary changes at 6-month follow-up CT and predictors of pulmonary residual abnormalities and fibrotic-like changes in COVID-19 pneumonia patients in China following relaxation of COVID restrictions in 2022. A total of 271 hospitalized patients with COVID-19 pneumonia admitted between November 29, 2022 and February 10, 2023 were prospectively evaluated at 6 months. CT characteristics and Chest CT scores of pulmonary abnormalities were compared between the initial and the 6-month CT. The association of demographic and clinical factors with CT residual abnormalities or fibrotic-like changes were assessed using logistic regression. Follow-up CT scans were obtained at a median of 177 days (IQR, 170-185 days) after hospital admission. Pulmonary residual abnormalities and fibrotic-like changes were found in 98 (36. 2%) and 39 (14. 4%) participants. In multivariable analysis of pulmonary residual abnormalities and fibrotic-like changes, the top three predictive factors were invasive ventilation (OR 13. 6; 95% CI 1. 9, 45; P  60 years (OR 9. 1; 95% CI 2. 3, 39; P = . 01), paxlovid (OR 0. 11; 95% CI 0. 04, 0. 48; P = . 01) and invasive ventilation (OR 10. 3; 95% CI 2. 9, 33; P = . 002), paxlovid (OR 0. 1; 95% CI 0. 03, 0. 48; P = . 01), smoker (OR 9. 9; 95% CI 2. 4, 31; P = . 01), respectively. The 6-month follow-up CT of recent COVID-19 pneumonia cases in China showed a considerable proportion of the patients with pulmonary residual abnormalities and fibrotic-like changes. Antivirals against SARS-CoV-2 like paxlovid may be beneficial for long-term regression of COVID-19 pneumonia.

Open Access PDF

Concepts Keywords
185days COVID-19
China Follow-up
Hospital Pneumonia
Pneumonia SARS-CoV-2
Tomography, X-ray


Type Source Name
disease MESH COVID-19
disease MESH Pneumonia
disease MESH abnormalities
disease MESH Long Covid
drug DRUGBANK Coenzyme M
disease MESH Acute respiratory distress syndrome
disease VO organ
disease MESH pulmonary fibrosis
disease MESH infections
disease VO Pla
disease MESH reinfection
disease VO protocol
disease MESH atelectasis
disease MESH bronchiectasis
disease MESH crazy paving pattern
disease MESH organizing pneumonia
disease MESH pleural effusion
drug DRUGBANK Trestolone
disease VO USA
drug DRUGBANK Sodium lauryl sulfate
disease MESH hypertension
disease MESH diabetes mellitus
disease MESH venous thromboembolism
drug DRUGBANK Oxygen
disease MESH ischemic heart disease
disease MESH COPD
disease VO age
drug DRUGBANK Medical air
disease VO time
disease VO population
disease IDO history
disease VO effective
disease IDO infection
disease VO efficiency
disease MESH fibrosis
drug DRUGBANK Guanosine
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Troleandomycin
disease MESH clinical significance
disease MESH influenza
disease MESH severe acute respiratory syndrome
disease MESH lung injury
disease MESH sequelae
disease MESH functional status
disease MESH convalescence
drug DRUGBANK Isosorbide Mononitrate
disease VO effectiveness
drug DRUGBANK Ritonavir
disease MESH emergency
disease MESH critically ill
drug DRUGBANK Dexamethasone
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)